Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Once "Erase the company like he did references to Prurisol and Kevetrin" Ehrlich loses his frivolous appeal, we may get an out-of-business press release.
As the great Yogi Berra once said "it ain't over til it's over" Nothing I can do now....worst case scenario is I take a tax loss.......I won't sell, I'd rather stay til the end...
I have a suspicion that the BeaMed holdings...
will be sold to a private party to satisfy the Beverly judgment. Probably for $1.5 - 1.6 to pay the judgment, plus accrued interest and expenses . And just who will this private party be? Why none other than Leo Ehrlich himself. Bought and paid for with the salary issued from the company over 15 years of failure, all from money derived from shareholders' investment.
Try your Fidelity again. Game over for online buys. Game over for Sham Ehrlich and his garbage dump. "Opening transactions for this security are not currently permitted due to its expert market designation and/or the risk associated with this security." It does seem like you can still unload this junk though once you are able to find the latest price. Still feeling upbeat about Ehrich and all those "buys" you have made?
What caught my eye in the last 10-Q (filed Nov 14, 2023) was the following:
Through the date of this report, management has been unable to secure additional financing, and the ability of the Company to continue as a going concern is becoming increasingly unlikely.
"Below is a study of a Kevetrin modification which reportedly increase its effectiveness 100X."
"In the present study, we designed and synthesized a novel analog (compound 900) of Kevetrin"
"Drug analogs, also known as structural analogs and chemical analogs, are compounds that have a structure similar to another compound but differ from it in certain components, such as functional groups or substructures."
https://www.bocsci.com/resources/what-are-drug-analogues.html
Is it proper to call the designed novel analog compound 900 "a Kevetrin modification" when it's actually a compound that has structure similar to Kevetrin but differs from it? If compound 900 was to be approved someday the approved compound would be described by its own structure and without language describing it as a Kevetrin modification, correct?
If this is true....
"The new analog 900 is >100 fold more potent than Kevetrin and holds great promise to be developed further for ovarian and other mechanistically relevant cancers"
.....then this may not be a reasonable belief:
"I do not believe the Kevetrin story is over"
IPIX has already raised the white flag over its kevetrin development. Obviously the drug itself hasn't disappeared but its benefit to IPIX investors, such as it was, seems to be history.
“ I don't think quiet introspection pays the bills.”
In my experience a calm assessment plus follow through has paid more bills than devoting my time and effort into wallowing in the mud while cursing the one who I believe failed me.
“In the end, pumping snowy clowns were merely fate’s cruel bait.”
You couldn’t be more wrong about ‘Snowy’ pumping IPIX. I’ve frequently been criticized for not talking about the company.
It’s weird how people with little to zero investment in IPIX continue to prattle on while flinging their feces. It seems abnormal.
1000% agree pete
I don't think quiet introspection pays the bills.
If they can't it will put a lot of people out of work here.
Poor bastards. In the end, pumping snowy clowns were merely fate’s cruel bait. The CEO won. Believers lost.
Exert Market what a kick in the 🫏
"The last10q Leo filed warned we could lose our status so maybe was planned who knows. "
Here's the last 10-Q:
https://www.sec.gov/Archives/edgar/data/1355250/000147793223008688/ipix_10q.htm#a13
On what page does Leo issue that warning? I don't think it's in there.
I believe you are thinking of the 10-K filed prior to that 10-Q and that warning concerned something entirely different:
"We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223007158/ipix_10k.htm
Electing to deregister a Company's shares (which was not done here) in order to suspend reporting obligations is 180 degrees from knowingly and intentionally failing to meet a Company's filing obligations. The former requires a filing certifying that the Company meets the standards to deregister while the latter results from the willful failure to perform a legal obligation.
That was a great article you posted; thanks much
I hope that if the day ever comes when K and B may prove to be the drugs we have expected them to be that we will still be around to enjoy some of the fruits of having owned it when it started.
Wish we had someone like you directing the path for IPIX instead of a bean counter.
The last10q Leo filed warned we could lose our status so maybe was planned who knows. Leo hired a new accounting firm. My question is why?
I have a garden to work on so at this point I'm checking out of this mess for a long while.
Thanks for the correction. I haven’t been following nearly as closely as in the past. K was the impetus for my initial investment.
Sadly this may just be a tax loss at some point.
I typically just let my small bio pharma marinate for many years as you never know.
What I’ve come to know 100% is that IpIx/CTIX will never succeed with Leo involved.
Your shares were worth around a penny. Whats hard to understand here? Before today, ipix was trading normally for years and the market came to the determination that a share of ipix was fairly valued at one cent.
In the USA per SEC rules that is what I gathered.
"Didn’t IpIx already sell/lose the rights to kevetrin?"
Neither, but with the same effect.....
From the last 10-K:
"At any time, we may decide to discontinue the development of, or to not commercialize, a drug candidate, such as our decision in December 2018 to discontinue the Prurisol psoriasis program, and our decision in September 2022 to discontinue the Kevetrin oncology program."
So they turned the buy button off and now only sells are possible?
Lol. What does anything you say have to do with the sorry state of this mess? Time to focus. Why don't you tell us what a great company this has become.
Didn’t IpIx already sell/lose the rights to kevetrin? Or I’m not recalling correctly?
Either way, I just noticed today that Schwab no longer accepts buy orders on IPiX. Sell only.
Pete I do not believe the Kevetrin story is over. Below is a study of a Kevetrin modification which reportedly increase its effectiveness 100X.Obvoiously more studies need to be done. Based of the results below I expect a whole series of studies based on these results.
In the present study, we designed and synthesized a novel analog (compound 900) of Kevetrin and its cytotoxicity was assessed using four different ovarian cancer cell lines viz. OVCAR-3, OVCAR-10, ES2, drug-resistant HeyA8 cells, and normal fibroblast cells (FHC). Compared to the control and Kevetrin, compound 900 inhibited the ovarian cancer cell viability in a dose- and time-dependent manner. The IC50 value of compound 900 was 0.8 µM, 0.7 µM, 0.8 µM, and 0.9 µM for OVCAR-3, HeyA8, OVCAR-10, and ES2 cells, respectively, while for Kevetrin the IC50 value was >100 µM for 48 h treatment. Compound 900 was thus found to be >100 times more potent than standard Kevetrin. To further acquaint the effect of 48 h treatment on cell proliferation, we performed trypan blue cell viability assay, trypan blue dye exclusion assay, Annexin V/7-AAD, Caspase 3/7 apoptosis assays, and Western blotting of apoptotic proteins involved in apoptosis. Compound 900 significantly induced apoptosis in OVCAR-3 and HeyA8 cells in a dose-dependent manner. Upregulation of several apoptotic proteins, as evident by Western blot, suggested that 900 causes the induction of apoptotic pathways efficiently. Further, the cell cycle analysis showed a significant arrest of OVCAR-3 and HeyA8 cells in the S-phase, which was further confirmed by the analysis of cyclin A2, cyclin-E1, p21, and p27 protein expression. Additionally, compound 900 caused a significant increase in the expression of the cell cycle inhibitory genes p21 and p27 in a p53-independent manner, compared to Kevetrin. Kevetrin has shown promise in preliminary clinical studies in solid tumor patients. The new analog 900 is >100 fold more potent than Kevetrin and holds great promise to be developed further for ovarian and other mechanistically relevant cancers.
Citation Format: Asif Raza, Jacek Krzeminski, Shantu Amin, Arun Sharma. Discovery of a novel Kevetrin analog as a potential therapeutic for ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1650.
Thanks snayeman. Yeah bids, asks are gone.
What a crock of shit that Leo let this happen!
Was it ever given a chance to make the cut? Last I heard it did real well with renal cancer in a trial with an already approved cancer drug but then nothing, even though it was deemed totally safe from P1. Didn't even make it into P2 though a leading cancer expert, Dr. Frei, who found the cure for juvenile leukemia,said he thought Kevetrin could be useful against 50% of ALL cancers.
Wouldn't surprise me in the least to find IPIX fails and then miraculously Kevetrin ends up in some private person's hands (a BP insider most likely) that makes a fortune off it.
Friggen' Cancer Society didn't contribute one damn dollar to try and further this drug. That to me showed they have no drive to find a cure, just a steady raising of money that leads nowhere but their salaries.
New England Journal of Medicine study of Paxlovid shows no conclusive benefit in high risk patients.
"Conclusions
The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir and those who received placebo. (Supported by Pfizer; EPIC-SR ClinicalTrials.gov number, NCT05011513.)"
"In this trial, we assessed the safety and efficacy of nirmatrelvir–ritonavir as an antiviral agent against SARS-CoV-2 in symptomatic, nonhospitalized, vaccinated or unvaccinated adults. Nirmatrelvir–ritonavir was not associated with a significantly shorter time to sustained alleviation of Covid-19 symptoms than placebo, and the usefulness of nirmatrelvir–ritonavir in patients who are not at high risk for severe Covid-19 has not been established."
Is it time for a Paxlovid vs Brilacidin clinical trial?
Farrell
It was Kevetrin not Brilacidin. It is a shame Kevetrin never made the cut for a clinical trial for retinoblastoma.
https://www.fdanews.com/articles/174349-cellceutixs-kevetrin-wins-rare-pediatric-disease-designation
Farrell
Where's frenchbroad?
Longs need him (Mr. Bean) now more than ever to attempt to drown out the noise of chickens coming home to roost.
Maybe he's beside the pool in Florida too and a bit too busy relaxing in the sun to calm the mayhem?
From 18 to 6…. This thing just keep amazing me :)
Got a link for that PollyAnna-ish analysis of the OTC "expert" market?
It so profoundly mis-states the reality that it must come from a conflicted source. Probably OTC Markets itself which has been desperately trying to make a silk purse out of the sow's ear that is the "Expert" Market.
Here's a dose of reality:
https://www.securitieslawyer101.com/2022/otc-markets-expert-market/
"... come out and say the company is out-of-business and some here would still believe hope exists."
Based on your frequency of posts it's apparent that you obsess about IPIX more than most professed shareholders. Quiet introspection can be extremely valuable.
Interesting read:
Trading on the Expert Market with restrictions such as "unsolicited quotes only" might seem primarily disadvantageous, but there are specific circumstances, such as during a merger, reverse merger, or buyout, where these conditions could potentially be advantageous or at least have neutral effects for the company involved. Here’s how:
Potential Advantages
1 Control Over Information: In scenarios involving significant corporate actions like mergers or acquisitions, controlling how information is disclosed to the public can be crucial. Being on the Expert Market, where quotations are restricted from public viewing and information release is tightly controlled, could help manage the timing and details of what is released, aligning it strategically with corporate goals.
2 Minimized Speculation: The restricted visibility and trading limitations might reduce speculative trading, which can sometimes lead to unwanted volatility in a company's stock price. In the delicate periods leading up to and during major corporate transitions, stability in the stock price can be beneficial.
3 Focused Investor Base: Since the Expert Market targets professional and institutional investors, companies may find that their stock is being held and handled by investors who have a better understanding of the complexities of mergers and acquisitions. This can lead to more rational pricing adjustments based on the fundamentals of the deal rather than on erratic market sentiment.
4 Ease of Transaction Execution: In some cases, especially during reverse mergers (where a private company merges with a public company primarily for the benefit of becoming publicly traded without undergoing a traditional initial public offering), the existing setup in the Expert Market might facilitate quicker execution of the deal. The professional investor base and the less stringent public disclosure requirements until the deal is finalized can ease the transition.
Potential Disadvantages
1 Limited Market Reaction: One of the challenges remains the limited exposure to a broader market, which can suppress the potential positive market reaction typically seen when public investors favorably view a merger or acquisition.
2 Investor Skepticism: Professional and institutional investors, while sophisticated, may be more critical and cautious, particularly when dealing with companies that have restrictions on their trading. This skepticism could potentially influence the terms of the deal unfavorably for existing shareholders.
3 Compliance and Legal Risks: Navigating the complexities of a merger or acquisition while on the Expert Market, especially under conditions like unsolicited quotes only, requires careful legal and compliance considerations. Missteps in this area could lead to significant regulatory or legal repercussions.
You should thank Schwab for not enabling you to buy this garbage.
Looks like 14 trades total but some just won't accept the fact that death is here despite all the negativity surrounding this mess. That sewer-dwelling CEO could finally come out and say the company is out-of-business and some here would still believe hope exists. Sad.
"Funny that the 3 trades that went thru this morning were all buys yet classified under question mark!!!!!!"
Gutsy move by somebody. Company has no money, board abandoned ship, a horrible CEO who has let this mess sink into the expert market, diminished trading market, no communication, no updates, no filings, no transparency. "Possibly" good for day traders who might make a few dollars speculating ( already down 43% today) but this will never be the positive life-changing stock that so many hoped it would be. Just another penny stock fiasco.
I think maybe if you call in your order and have a broker execute the buy like the old days you can possibly buy! You can’t buy on internet as it shows no accurate bid and ask! Not sure though
It worked on Fidelity.....
Tried E-trade, not excepting buys.
Funny that the 3 trades that went thru this morning were all buys yet classified under question mark!!!!!!
I can no longer buy IPIX using Schwab:
"Your order cannot be accepted. This security IPIX is accepting closing transactions only. (DO911)"
Last Price x Size / Exch
Last price: 0.0195 up +0.0018 up (+10.17%)
Somebody's buying
So much for all the drama, my buy order was just filled.....carry on mates!!!!!
There's a risk-free way you can find out if people can buy it assuming you have an online brokerage account.
Enter an order to buy 100 shares. You SHOULD get a screen that asks you to click CONFIRM or CANCEL so you can avoid placing an order if that's your choice. But before you reach that point you might get a note advising that the shares are traded in the Expert Market and describing your options.
Followers
|
976
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
403044
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |